Literature DB >> 28559142

AG1296 enhances plaque stability via inhibiting inflammatory responses and decreasing MMP-2 and MMP-9 expression in ApoE-/- mice.

Min Dong1, Changping Zhou1, Liang Ji1, Bing Pan2, Lemin Zheng3.   

Abstract

BACKGROUND: Atherosclerosis is a chronic process that progresses to unstable plaques. Plaque rupture leads to deleterious consequences such as acute coronary syndrome, thrombosis and stroke. AG1296 is a potent tyrosine kinase inhibitor which is able to block PDGF-PDGFR signaling pathway. This study aims to assess the effect of AG1296 on plaque stability and explore the potential mechanisms.
METHODS: Atherosclerotic plaques were induced in carotid arteries in ApoE-/- mice by perivascular collar placement. All mice were randomly divided into PBS and AG1296 groups. 3 weeks after the surgery, the carotid arteries were harvested for histological analysis.
RESULTS: In AG1296 group, plaque area decreased by 41.5% (p = 0.0041) and the contents of macrophages and lipids decreased by 43.5% (p = 0.0003) and 35.6% (p = 0.0032) respectively. The contents of smooth muscle cells increased by 22.3% (p = 0.0214) in AG1296 group. Vulnerable index decreased by 48.3% (p = 0.0002). The inflammation factors IL-6 and TNF- alpha decreased by 49.0% (p = 0.0008) and 51.8% (p < 0.0001) and matrix metalloproteinases MMP-2 and MMP-9 decreased by 54.1% (p = 0.0004) and 37.1% (p < 0.0001) in AG1296 group. M1 macrophage markers (MCP-1) were downregulated by 30.3% (p = 0.0007) and M2 macrophage markers (ARG-1) were increased by 55.2% (p = 0.0009) in AG1296 group.
CONCLUSION: AG1296 inhibited the atherosclerotic plaque progression and enhanced plaque stability by inhibiting inflammatory responses, reducing the expression of matrix metalloproteinases and promoting macrophages from proinflammatory phenotype to anti-inflammatory phenotype.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Inflammation; Matrix metalloproteinases; Plaque stability

Mesh:

Substances:

Year:  2017        PMID: 28559142     DOI: 10.1016/j.bbrc.2017.05.159

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Changes in interleukin-27 levels in patients with acute coronary syndrome and their clinical significance.

Authors:  Lin Zhang; Junfeng Zhang; Shaohong Su; Suyan Luo
Journal:  PeerJ       Date:  2019-01-04       Impact factor: 2.984

2.  LOX inhibition downregulates MMP-2 and MMP-9 in gastric cancer tissues and cells.

Authors:  Lei Zhao; Haiya Niu; Yutao Liu; Lei Wang; Ning Zhang; Gaiqiang Zhang; Rongqing Liu; Mei Han
Journal:  J Cancer       Date:  2019-10-20       Impact factor: 4.207

3.  Feprazone Prevents Free Fatty Acid (FFA)-Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway.

Authors:  Min Song; Liukun Meng; Xiaoxi Liu; Yan Yang
Journal:  ACS Omega       Date:  2021-02-09

4.  Intermedin1-53 attenuates atherosclerotic plaque vulnerability by inhibiting CHOP-mediated apoptosis and inflammasome in macrophages.

Authors:  Jin-Ling Ren; Yao Chen; Lin-Shuang Zhang; Ya-Rong Zhang; Shi-Meng Liu; Yan-Rong Yu; Mo-Zhi Jia; Chao-Shu Tang; Yong-Fen Qi; Wei-Wei Lu
Journal:  Cell Death Dis       Date:  2021-05-01       Impact factor: 8.469

5.  Effects of withdrawing an atherogenic diet on the atherosclerotic plaque in rabbits.

Authors:  Lijun Zhao; Shifang Zhang; Qiaoli Su; Shuangqing Li
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

Review 6.  Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations.

Authors:  Xiaoxin Li; Yanyan Yang; Zhibin Wang; Shaoyan Jiang; Yuanyuan Meng; Xiaoxia Song; Liang Zhao; Lu Zou; Min Li; Tao Yu
Journal:  Int J Biol Sci       Date:  2021-08-03       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.